{"id":"neoadjuvant-folfox","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Neutropenia"},{"rate":"30-40","effect":"Nausea and vomiting"},{"rate":"20-30","effect":"Diarrhea"},{"rate":"15-25","effect":"Peripheral neuropathy"},{"rate":"20-30","effect":"Anemia"},{"rate":"10-20","effect":"Mucositis"},{"rate":"30-40","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL414804","moleculeType":"Small molecule","molecularWeight":"395.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FOLFOX combines 5-fluorouracil (5-FU), leucovorin (folinic acid), and oxaliplatin. 5-FU inhibits thymidylate synthase and is incorporated into DNA/RNA to disrupt synthesis. Oxaliplatin is a platinum agent that forms DNA cross-links, preventing replication. Leucovorin enhances 5-FU efficacy. In neoadjuvant therapy, the regimen is administered preoperatively to reduce tumor burden and improve surgical outcomes.","oneSentence":"FOLFOX is a combination chemotherapy regimen that damages cancer cell DNA through multiple mechanisms to inhibit tumor growth and is used in the neoadjuvant setting to shrink tumors before surgery.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:48.983Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neoadjuvant treatment of locally advanced colorectal cancer"},{"name":"Gastric and gastroesophageal junction cancers (neoadjuvant setting)"}]},"trialDetails":[{"nctId":"NCT02758951","phase":"PHASE2, PHASE3","title":"Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Koen Rovers","startDate":"2017-06-01","conditions":"Colorectal Neoplasm, Colorectal Cancer, Colorectal Neoplasms Malignant","enrollment":358},{"nctId":"NCT07472868","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"J. W. A. Burger","startDate":"2026-03-03","conditions":"Locally Advanced Rectal Carcinoma","enrollment":394},{"nctId":"NCT05733689","phase":"PHASE1","title":"Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2025-06-27","conditions":"Gastroesophageal Adenocarcinoma","enrollment":20},{"nctId":"NCT04757363","phase":"PHASE2","title":"A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-02-11","conditions":"Esophagogastric Cancer, HER2-Negative","enrollment":39},{"nctId":"NCT04215731","phase":"PHASE3","title":"Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Yanhong Deng","startDate":"2020-03-27","conditions":"Rectal Cancer","enrollment":582},{"nctId":"NCT03483038","phase":"PHASE2","title":"A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2018-12-13","conditions":"Pancreatic Adenocarcinoma","enrollment":45},{"nctId":"NCT07406126","phase":"","title":"Yttrium-90 Radioembolization Neoadjuvant Therapy With Immune Marker Profiling and Dosimetry for Potentially Resectable Patients With Colorectal Liver Metastases","status":"NOT_YET_RECRUITING","sponsor":"Fernando Gómez Muñoz","startDate":"2026-02","conditions":"Colorectal Liver Metastases (CRCLM), Unresectable Colorectal Liver Metastases","enrollment":30},{"nctId":"NCT05673772","phase":"PHASE2","title":"Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyungpook National University Hospital","startDate":"2020-10-23","conditions":"Rectal Cancer","enrollment":364},{"nctId":"NCT03516708","phase":"PHASE1, PHASE2","title":"Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2020-01-06","conditions":"Rectal Cancer","enrollment":49},{"nctId":"NCT03426904","phase":"PHASE3","title":"Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyungpook National University Hospital","startDate":"2020-10-23","conditions":"Colon Cancer","enrollment":708},{"nctId":"NCT06107920","phase":"PHASE3","title":"Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2024-05-07","conditions":"Colon Cancer","enrollment":232},{"nctId":"NCT05412082","phase":"PHASE1","title":"SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"University of Miami","startDate":"2022-10-05","conditions":"Locally Advanced Rectal Cancer","enrollment":25},{"nctId":"NCT02959879","phase":"PHASE2","title":"Neo-adjuvant FOLF(IRIN)OX for Resectable Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2017-03-01","conditions":"Resectable Pancreatic Duct Adenocarcinoma","enrollment":153},{"nctId":"NCT04495088","phase":"PHASE3","title":"Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Ralf Hofheinz","startDate":"2020-09-30","conditions":"Rectal Cancer","enrollment":550},{"nctId":"NCT06688786","phase":"NA","title":"A Pospective, Single-arm, Multicenter Clinical Trial Evaluating Preoperative Neoadjuvant mFOLFOX6 Chemotherapy in Combination With PD1 Monoclonal Antibody in MSS/pMMR Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2024-11-01","conditions":"Locally Advanced Rectal Cancer (LARC)","enrollment":30},{"nctId":"NCT05855200","phase":"PHASE3","title":"Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2023-08-01","conditions":"Colonic Neoplasms, Neoplasms, Colon","enrollment":892},{"nctId":"NCT06205485","phase":"PHASE3","title":"Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2024-06-26","conditions":"Rectal Cancer","enrollment":250},{"nctId":"NCT03921684","phase":"PHASE2","title":"Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baruch Brenner","startDate":"2019-04-10","conditions":"Rectal Cancer","enrollment":29},{"nctId":"NCT05171166","phase":"PHASE2, PHASE3","title":"Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.","status":"TERMINATED","sponsor":"Peking University","startDate":"2021-12-24","conditions":"Hepatocellular Carcinoma","enrollment":18},{"nctId":"NCT07101666","phase":"PHASE2","title":"Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-01-31","conditions":"Gastric Cancer","enrollment":20},{"nctId":"NCT07257380","phase":"PHASE2","title":"Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-12-30","conditions":"Gastric / Gastroesophageal Junction Adenocarcinoma","enrollment":90},{"nctId":"NCT06154538","phase":"PHASE2","title":"Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-11-01","conditions":"Locally Advanced Colorectal Carcinoma","enrollment":170},{"nctId":"NCT07248020","phase":"PHASE2","title":"A Phase II Single-Arm Study of High-Bioavailability Curcumin as Neoadjuvant Chemoradiotherapy in Mid-to-Low Rectal Cancer: Integrated Clinical and Translational Analysis of Tumor Tissue","status":"NOT_YET_RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2026-01-01","conditions":"Rectal Cancer, Locally Advanced Rectal Cancer, Radiation-Induced Enteritis","enrollment":72},{"nctId":"NCT06783491","phase":"PHASE3","title":"Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer","status":"NOT_YET_RECRUITING","sponsor":"Maimónides Biomedical Research Institute of Córdoba","startDate":"2025-12-31","conditions":"Locally Advanced Colorectal Cancer","enrollment":1083},{"nctId":"NCT04656041","phase":"PHASE2","title":"Folfox+Irinotecan+Chemort In Esophageal Cancer","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2021-06-29","conditions":"Gastroesophageal Junction Adenocarcinoma, Esophagogastric Cancer","enrollment":40},{"nctId":"NCT04104139","phase":"PHASE1","title":"TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2019-12-11","conditions":"Rectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8","enrollment":19},{"nctId":"NCT06467799","phase":"PHASE2","title":"Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-09-01","conditions":"Hepatocellular Carcinoma, Beyond Milan Criteria","enrollment":39},{"nctId":"NCT02008656","phase":"PHASE2","title":"Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-11","conditions":"Rectal Cancer","enrollment":358},{"nctId":"NCT07134218","phase":"PHASE2, PHASE3","title":"Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Changhai Hospital","startDate":"2025-10","conditions":"Rectal Cancer","enrollment":180},{"nctId":"NCT07118800","phase":"PHASE3","title":"Study Evaluating Two Treatment Strategies for Rectal Cancer in Patients ≥75 Years Old","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2025-12-15","conditions":"Locally Advanced Rectal Adenocarcinoma","enrollment":160},{"nctId":"NCT06958419","phase":"PHASE2, PHASE3","title":"Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC)","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2025-05-01","conditions":"Immune Checkpoint Therapy, Radiotherapy, Metastatic Colorectal Cancer (CRC)","enrollment":286},{"nctId":"NCT06856187","phase":"PHASE2","title":"Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-02-28","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":119},{"nctId":"NCT07074353","phase":"PHASE3","title":"Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-07-20","conditions":"Locally Advanced Rectal Cancer","enrollment":360},{"nctId":"NCT04864067","phase":"PHASE2","title":"No Operation After Short Course Radiotherapy Followed By Consolidation Chemotherapy In Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Servicio de Salud Metropolitano Sur Oriente","startDate":"2021-06-09","conditions":"Rectal Cancer","enrollment":73},{"nctId":"NCT06280495","phase":"PHASE2, PHASE3","title":"Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-02-01","conditions":"Colorectal Cancer, Liver Metastases","enrollment":156},{"nctId":"NCT06972498","phase":"PHASE2","title":"A Prospective Multicenter Study: Ivosimab + Chemotherapy as Neoadjuvant for Resectable pMMR/MSS CRC Liver Mets","status":"NOT_YET_RECRUITING","sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","startDate":"2025-07-01","conditions":"Colorectal Cancer With Liver Metastasis","enrollment":35},{"nctId":"NCT03548961","phase":"PHASE2","title":"Organ Preservation in Early Rectal Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2018-05-11","conditions":"Rectal Cancer","enrollment":19},{"nctId":"NCT06904014","phase":"PHASE2","title":"Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC","status":"RECRUITING","sponsor":"Lei ZHAO","startDate":"2023-10-25","conditions":"HCC","enrollment":40},{"nctId":"NCT06293625","phase":"PHASE3","title":"Personalising and Refining Neo-adjuvant Chemotherapy in Locally Advanced but Resecable Colon Cancer in the Elderly of 70 Years Old or More","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2024-06-07","conditions":"Colon Cancer","enrollment":150},{"nctId":"NCT04460352","phase":"PHASE3","title":"Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer","status":"RECRUITING","sponsor":"Karolinska University Hospital","startDate":"2020-11-27","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":1020},{"nctId":"NCT06857773","phase":"PHASE3","title":"Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic Therapy","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2024-11-21","conditions":"Colorectal Neoplasms, Floxuridine, Liver Metastases","enrollment":306},{"nctId":"NCT06844409","phase":"","title":"Neoadjuvant FOLFOX Chemotherapy for Colon Cancer: Long-Term Chemotherapy-Induced Peripheral Neuropathy and Impact on Quality of Life","status":"COMPLETED","sponsor":"P. Herzen Moscow Oncology Research Institute","startDate":"2021-03-19","conditions":"Chemotherapy Induced Peripheral Neuropathy (CIPN)","enrollment":54},{"nctId":"NCT06225843","phase":"PHASE2","title":"Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis","status":"RECRUITING","sponsor":"Alethia Biotherapeutics","startDate":"2024-02-15","conditions":"Metastatic Colorectal Cancer","enrollment":17},{"nctId":"NCT06831981","phase":"NA","title":"Hyperthermia With Chemoradiotherapy in Rectal Cancer","status":"RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2024-09-11","conditions":"Rectal Cancer","enrollment":264},{"nctId":"NCT05296005","phase":"PHASE1","title":"Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers","status":"WITHDRAWN","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2025-12-31","conditions":"Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage IIA Gastric Cancer AJCC v8","enrollment":""},{"nctId":"NCT02000050","phase":"PHASE2","title":"Phase II Study of Up-front Chemotherapy and Neo-adjuvant Short-course Radiotherapy for Resectable Rectal Carcinoma (COLORE)","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2013-10-11","conditions":"Rectal Carcinoma","enrollment":52},{"nctId":"NCT04162665","phase":"PHASE2","title":"Pre-operative Adaptive Short Court Radiation Therapy in Gastric Cancer","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2020-02-14","conditions":"Gastric Adenocarcinoma","enrollment":4},{"nctId":"NCT06758830","phase":"PHASE2, PHASE3","title":"Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.","status":"RECRUITING","sponsor":"National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos","startDate":"2025-01-07","conditions":"Rectal Cancer, Total Neoadjuvant Treatment, Neoadjuvant Therapy","enrollment":400},{"nctId":"NCT02843191","phase":"PHASE3","title":"Consolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After Neoadjuvant Concurrent Chemoradiotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyung Hee University Hospital at Gangdong","startDate":"2016-12-07","conditions":"Rectal Cancer","enrollment":358},{"nctId":"NCT03781323","phase":"PHASE2","title":"Neoadjuvant FOLFOX Therapy With Short Course Radiation and Active Surveillance in Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Rochester","startDate":"2019-05-03","conditions":"Advanced Rectal Cancer","enrollment":12},{"nctId":"NCT04679597","phase":"","title":"Total Neoadjuvant Therapy Versus Standard Therapy of Locally Advanced Rectal Cancer With High Risk Factors for Failure","status":"COMPLETED","sponsor":"Institute of Oncology Ljubljana","startDate":"2016-01-01","conditions":"Rectal Cancer","enrollment":161},{"nctId":"NCT03259035","phase":"PHASE2","title":"NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer","status":"COMPLETED","sponsor":"Canadian Cancer Trials Group","startDate":"2018-06-29","conditions":"Rectal Cancer","enrollment":58},{"nctId":"NCT05496491","phase":"NA","title":"Neoadjuvant Chemoradiotherapy and Consolidation Chemotherapy for Rectal Cancer: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"Larissa University Hospital","startDate":"2022-08-30","conditions":"Rectal Neoplasms","enrollment":84},{"nctId":"NCT01274962","phase":"PHASE2","title":"A Study on the Timing of FOLFOX for Patients With Operable, Node Positive Rectal Cancer","status":"COMPLETED","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2009-11","conditions":"Operable T2-3N+M0 Rectal Cancer (Stage III)","enrollment":180},{"nctId":"NCT05068531","phase":"","title":"Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients","status":"RECRUITING","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2022-09-01","conditions":"Colorectal Cancer Metastatic","enrollment":100},{"nctId":"NCT06296563","phase":"PHASE2","title":"Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC","status":"RECRUITING","sponsor":"Lei ZHAO","startDate":"2024-03-01","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":20},{"nctId":"NCT01515787","phase":"PHASE2, PHASE3","title":"PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery","status":"UNKNOWN","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2012-06-12","conditions":"Colorectal Cancer","enrollment":1194},{"nctId":"NCT03698461","phase":"PHASE2","title":"Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2019-05-15","conditions":"Colorectal Neoplasms, Neoplasm Metastasis, Colonic Neoplasms","enrollment":20},{"nctId":"NCT06235164","phase":"","title":"The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer","status":"UNKNOWN","sponsor":"Fujian Medical University","startDate":"2019-01-01","conditions":"Locally Advanced Gastric Cancer","enrollment":585},{"nctId":"NCT05526079","phase":"PHASE2","title":"Watchful Waiting for Complete Responders to Therapy in Rectal Cancer","status":"RECRUITING","sponsor":"Henry Ford Health System","startDate":"2018-07-10","conditions":"Rectal Cancer","enrollment":30},{"nctId":"NCT04308837","phase":"PHASE2","title":"A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation","status":"UNKNOWN","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2018-12-03","conditions":"Gastric Cancer, Stomach Cancer","enrollment":29},{"nctId":"NCT02243358","phase":"PHASE2","title":"Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer","status":"COMPLETED","sponsor":"Henry Ford Health System","startDate":"2014-02","conditions":"Pancreas Neoplasm Malignant Resectable","enrollment":24},{"nctId":"NCT06097416","phase":"PHASE3","title":"Neoadjuvant Chemoradiotherapy Versus Total Neoadjuvant Therapy in the Treatment of T3 Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"St. James's Hospital, Ireland","startDate":"2024-10","conditions":"Rectal Cancer","enrollment":100},{"nctId":"NCT05250843","phase":"PHASE2, PHASE3","title":"TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2022-05-30","conditions":"Hepatocellular Carcinoma","enrollment":90},{"nctId":"NCT01606098","phase":"PHASE3","title":"The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer","status":"COMPLETED","sponsor":"Dutch Colorectal Cancer Group","startDate":"2012-07","conditions":"Colon Cancer, Primary Tumour, Rectal Cancer","enrollment":206},{"nctId":"NCT05984485","phase":"PHASE3","title":"The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-07-05","conditions":"Rectal Cancer","enrollment":766},{"nctId":"NCT05861505","phase":"PHASE3","title":"COLLISION RELAPSE Trial","status":"RECRUITING","sponsor":"Amsterdam UMC, location VUmc","startDate":"2023-04-24","conditions":"Colorectal Cancer, Liver Metastases, Liver Metastasis Colon Cancer","enrollment":360},{"nctId":"NCT03941366","phase":"NA","title":"Treatment of Adenocarcinoma of the Rectum With Transanal Local Excision for Complete Responders","status":"UNKNOWN","sponsor":"Henry Ford Health System","startDate":"2016-02-26","conditions":"Rectal Cancer","enrollment":15},{"nctId":"NCT01558921","phase":"PHASE3","title":"Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2011-06-21","conditions":"Rectal Cancer","enrollment":920},{"nctId":"NCT05673343","phase":"","title":"The Prognostic Impact Of The Neutrophil To Lymphocyte Ratio In Patients With Locally Advanced Rectal Cancer","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-01-04","conditions":"the Prognostic Value of Pre-treatment NLR in Patients With Locally Advenced Rectal Cancer and Post-treatment","enrollment":100},{"nctId":"NCT01212822","phase":"PHASE2","title":"Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer","status":"COMPLETED","sponsor":"Fox Chase Cancer Center","startDate":"2011-04-27","conditions":"Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach","enrollment":20},{"nctId":"NCT04389086","phase":"PHASE3","title":"Induction Chemotherapy for Locally Recurrent Rectal Cancer","status":"RECRUITING","sponsor":"Catharina Ziekenhuis Eindhoven","startDate":"2020-11-13","conditions":"Recurrent Rectal Cancer","enrollment":364},{"nctId":"NCT05378919","phase":"PHASE2","title":"Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Lithuanian University of Health Sciences","startDate":"2015-06-01","conditions":"Neoadjuvant Therapy in Rectal Cancer, Radiotherapy, FOLFOX","enrollment":250},{"nctId":"NCT05352165","phase":"NA","title":"The Clinical Efficacy of Drug Sensitive Neoadjuvant Chemotherapy Based on Organoid Versus Traditional Neoadjuvant Chemotherapy in Advanced Rectal Cancer","status":"UNKNOWN","sponsor":"Shanghai Minimally Invasive Surgery Center","startDate":"2023-01-01","conditions":"Neoadjuvant Therapy","enrollment":192},{"nctId":"NCT03957733","phase":"PHASE2, PHASE3","title":"Phase II/III Study to Assess the Efficacy of Neoadjuvant Consolidation Chemotherapy in Rectal Cancer Patients.","status":"UNKNOWN","sponsor":"King Abdullah Medical City","startDate":"2017-11-23","conditions":"Rectal Cancer","enrollment":338},{"nctId":"NCT05274945","phase":"PHASE2","title":"Total Neoadjuvant Therapy Versus Standard Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2020-01-01","conditions":"Rectal Cancer","enrollment":58},{"nctId":"NCT03939962","phase":"PHASE2","title":"Camrelizumab Combined With FOLFOX Neoadjuvant Therapy for Resectable Gastric and Gastroesophageal Junctional Adenocarcinoma","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2019-07-24","conditions":"Gastric Cancer","enrollment":60},{"nctId":"NCT05194878","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-12-01","conditions":"Colon Cancer Stage II, Colon Cancer Stage III","enrollment":840},{"nctId":"NCT02319304","phase":"PHASE2","title":"Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed Rectal Adenocarcinoma","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2015-03","conditions":"Rectal Adenocarcinoma","enrollment":3},{"nctId":"NCT05079503","phase":"NA","title":"Gut Microbiome and Its Immune Modulation in Locally Advanced Rectal Cancer","status":"UNKNOWN","sponsor":"Korean Cancer Study Group","startDate":"2021-12-15","conditions":"Locally Advanced Rectal Cancer","enrollment":40},{"nctId":"NCT04889820","phase":"NA","title":"Outcome of Neoadjuvant Chemotherapy for Obstructive Colon Cancer","status":"NOT_YET_RECRUITING","sponsor":"The Catholic University of Korea","startDate":"2021-11-01","conditions":"Colon Cancer, Obstruction","enrollment":204},{"nctId":"NCT02167321","phase":"PHASE2","title":"Rectal Cancer, Adjuvant Chemotherapy, FOLFOX(5-fluorouracil/Leucovorin/Oxaliplatin), Total Mesorectal Excision","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2014-12","conditions":"Locally Advanced Rectal Cancer","enrollment":90},{"nctId":"NCT04777942","phase":"NA","title":"Neo-TACE-HAIC for High-risk BCLC A Stage HCC (NeoconceptA)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-02-20","conditions":"Hepatocellular Carcinoma","enrollment":320},{"nctId":"NCT04621370","phase":"PHASE2","title":"A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer","status":"UNKNOWN","sponsor":"Liz-Anne Lewsley","startDate":"2020-12-07","conditions":"Rectal Cancer, Rectal Adenocarcinoma, Rectal Neoplasms","enrollment":48},{"nctId":"NCT04424043","phase":"NA","title":"Neo-TACE-HAIC for BCLC B Stage HCC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-07-08","conditions":"Hepatocellular Carcinoma","enrollment":280},{"nctId":"NCT04181931","phase":"NA","title":"Neo-TACE-HAIC for PVTT-HCC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-12-16","conditions":"Hepatocellular Carcinoma, Portal Vein Thrombosis","enrollment":320},{"nctId":"NCT03310008","phase":"PHASE1","title":"Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases","status":"UNKNOWN","sponsor":"Celyad Oncology SA","startDate":"2017-08-07","conditions":"Colon Cancer Liver Metastasis","enrollment":36},{"nctId":"NCT01363843","phase":"PHASE2","title":"Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)","status":"COMPLETED","sponsor":"William Sikov MD","startDate":"2010-05","conditions":"Colon Cancer, Rectal Cancer","enrollment":39},{"nctId":"NCT00541112","phase":"PHASE2","title":"Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery","status":"TERMINATED","sponsor":"UNICANCER","startDate":"2007-10-29","conditions":"Colorectal Cancer","enrollment":19},{"nctId":"NCT03323424","phase":"PHASE2","title":"Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers","status":"WITHDRAWN","sponsor":"Institut de Cancérologie de la Loire","startDate":"2019-01-01","conditions":"Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Head and Neck Cancer","enrollment":""},{"nctId":"NCT03022734","phase":"PHASE2","title":"Short Course Radiotherapy, Unresectable Rectal Cancer, Liver Metastasis","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2016-09","conditions":"Rectal Cancer, Metastatic","enrollment":40},{"nctId":"NCT00580073","phase":"PHASE2","title":"Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2007-12","conditions":"Rectal Cancer","enrollment":6},{"nctId":"NCT01650428","phase":"PHASE2","title":"Bevacizumab And Combination Chemotherapy in Rectal Cancer Until Surgery","status":"COMPLETED","sponsor":"University College, London","startDate":"2013-04","conditions":"Rectal Cancer","enrollment":20},{"nctId":"NCT03975049","phase":"PHASE3","title":"Triplet Combination or Doublet Regimen Versus Chemoradiation as Neoadjuvant Therapy for Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2019-08","conditions":"Rectal Cancer, Chemotherapy Effect","enrollment":933},{"nctId":"NCT03899870","phase":"","title":"Factors Predicting Recurrence in Rectal Cancer After Surgery","status":"COMPLETED","sponsor":"ammar houssem","startDate":"2000-01-01","conditions":"Rectal Cancer, Rectal Adenocarcinoma","enrollment":188},{"nctId":"NCT00613080","phase":"PHASE2","title":"Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2008-04","conditions":"Colorectal Cancer","enrollment":79},{"nctId":"NCT03469479","phase":"PHASE3","title":"Neoadjuvant HAIC for Resectable Hepatocellular Carcinoma Beyond Milan Criteria","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-03-02","conditions":"Hepatocellular Carcinoma","enrollment":252},{"nctId":"NCT03377842","phase":"PHASE2","title":"Apatinib Treatment as the Neoadjuvant Therapy in Advanced Colorectal Cancer","status":"UNKNOWN","sponsor":"Sichuan Provincial People's Hospital","startDate":"2018-01-31","conditions":"Colorectal Cancer, Neoadjuvant Therapy","enrollment":100},{"nctId":"NCT03280407","phase":"PHASE2","title":"NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal Cancer","status":"UNKNOWN","sponsor":"Zealand University Hospital","startDate":"2017-03-01","conditions":"Colorectal Neoplasm, Colorectal Cancer, Rectal Neoplasms","enrollment":124},{"nctId":"NCT01060007","phase":"PHASE2","title":"Five Fractions of Radiotherapy Followed by Full Dose FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2009-11","conditions":"Rectal Neoplasms","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":41,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Neoadjuvant FOLFOX","genericName":"Neoadjuvant FOLFOX","companyName":"Kyungpook National University Hospital","companyId":"kyungpook-national-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Neoadjuvant FOLFOX is a chemotherapy regimen used to treat various types of cancer, including gastric cancer, stomach cancer, colonic neoplasms, colon cancer, and neoplasms. The regimen involves the use of oxaliplatin, a small molecule DNA inhibitor, in combination with other drugs, such as paclitaxel and carboplatin, to target and inhibit cancer cells.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}